Sharon Townson Biography and Net Worth

Sharon originally joined Monte Rosa as Chief Technology Officer and brings expertise in molecular glues and targeted protein degradation technology platforms. She joined the Company from Kymera Therapeutics, where she served as Executive Director of Platform Biology. Previously, she was on the leadership team of Warp Drive Bio and was responsible for developing their novel molecular glue approach to target KRAS. Sharon began her career at Pfizer as a structural biologist and holds a Ph.D. in structural biology and biochemistry from the University of Manchester Institute of Technology.

What is Sharon Townson's net worth?: The estimated net worth of Sharon Townson is at least $1.24 million as of June 17th, 2026. Townson owns 67,845 shares of Monte Rosa Therapeutics stock worth more than $1,242,242 as of June 19th. This net worth approximation does not reflect any other investments that Townson may own. Learn More about Sharon Townson's net worth.
How do I contact Sharon Townson?: The corporate mailing address for Townson and other Monte Rosa Therapeutics executives is , , . Monte Rosa Therapeutics can also be reached via phone at 617-949-2643 and via email at [email protected]. Learn More on Sharon Townson's contact information.
Has Sharon Townson been buying or selling shares of Monte Rosa Therapeutics?: During the last ninety days, Sharon Townson has sold $57,000.00 in shares of Monte Rosa Therapeutics stock. Most recently, Sharon Townson sold 3,000 shares of the business's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $19.00, for a transaction totalling $57,000.00. Following the completion of the sale, the insider now directly owns 67,845 shares of the company's stock, valued at $1,289,055. Learn More on Sharon Townson's trading history.
Who are Monte Rosa Therapeutics' active insiders?: Monte Rosa Therapeutics' insider roster includes Jennifer Champoux (COO), Philip Nickson (Insider), Sharon Townson (Insider), and Markus Warmuth (CEO). Learn More on Monte Rosa Therapeutics' active insiders.
Are insiders buying or selling shares of Monte Rosa Therapeutics?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 49,967 shares worth more than $938,933.95. The most recent insider tranaction occured on June, 17th when COO Jennifer Champoux sold 2,176 shares worth more than $41,344.00. Insiders at Monte Rosa Therapeutics own 6.4% of the company. Learn More about insider trades at Monte Rosa Therapeutics.
Information on this page was last updated on 6/17/2026.

Sharon Townson Insider Trading History at Monte Rosa Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/17/2026	Sell	3,000	$19.00	$57,000.00	67,845

Sharon Townson Buying and Selling Activity at Monte Rosa Therapeutics

Monte Rosa Therapeutics Company Overview

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $18.31

$17.91

$19.31

50 Day Range

MA: $18.63

$16.37

$20.98

2 Week Range

Now: $18.31

$4.12

$25.77

Volume

2,507,725 shs

Average Volume

944,896 shs

Market Capitalization

$1.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6